Seminar #24A

The Merck Global Health Integrated Approach:  Health Solutions for Most Vulnerable Populations

Merck

No invitations necessary; open to all conference registrants

Monday, 5 December
12:30-14:00
CTICC room location: 1.61-1.62

TARGET AUDIENCE:
Local and global leaders in the field of infectious diseases as well as in the area of diagnostics.  National and international stakeholders from academia, NGOs, governments, local and international organizations, private sector.

SEMINAR DESCRIPTION:

The Merck seminar will introduce the Merck Global Health approach and organization by sharing high level vision and strategy as well as current initiatives and programs in focus.

The Global Health group is working to address key unmet medical needs related to infectious diseases, such as malaria, schistosomiasis and related microbial infections, with a focus on most vulnerable populations (children and mothers) in developing countries.

The goal is to develop innovative, affordable, implementable and integrated health solutions (including drugs, diagnostics, medical devices and digital health tools) leveraging Merck competencies. The approach being applied is based on public-private partnerships and collaborations with leading global health institutions and organizations in both developed and developing countries.

The seminar will also aim to exchange and showcase about the Merck efforts in the area of diagnostics. Beyond sharing about the development of new diagnostics (for e.g. malaria), the presentation will focus on the Muse® cytometry platform developed and launched for CD4 monitoring for HIV patients in sub-Saharan Africa and other developing regions.

The Muse Cell Analyzer is a highly intuitive, compact instrument for the fluorescent-based, 3-parameter analysis of cell populations. It uses miniaturized fluorescent detection and micro-capillary technology to deliver truly accurate, precise and quantitative cell analysis.

SESSION LEARNING OBJECTIVES:

Private sector perspective and contribution towards solving global health challenges

  • Innovative integrated approach in the fight against infectious diseases, considering detection, prevention, treatment and control of the disease.
  • Approach to diagnostics, with focus on the Muse cytometry platform.
  • Elements of drug discovery and development path.
  • Opportunities to engage for potential private-public collaborations

SESSION SPEAKERS:

Beatrice Greco, Merck, Director Malaria & Diagnostics, Global Health
Béatrice Gréco is Director, Malaria and Diagnostics for the Global Health organization. She is responsible for building up a mini portfolio of anti-malarial solutions spanning from new drugs to medical devices, associated with diagnostics allowing the identification of malarial infections as well as non-malarial fevers. Her responsibility extends also to developing new schistosomiasis diagnostics.

Beatrice has almost 20 year experience in academia and industrial translational drug discovery with a strong background in neurological therapeutic areas. She has held several managerial positions and led a number of preclinical development programs. She is also the co-founder of EspeRare, a non-for-profit organization dedicated to develop new therapeutic options for patients suffering from rare diseases.

Beatrice has studied neurosciences at Pierre et Marie Curie University in Paris, she holds a Ph.D. from Emory University (USA) that was followed by a post-doctoral position and an assistant professor position at the University Medical School of Massachusetts (MA, USA).

James Mulry, Merck, Head of Diagnostics, Global Health
Jim Mulry is the Head of Diagnostics for the Global Health organization. He is responsible for diagnostics-related activities within the two Innovation Clusters of Schistosomiasis/other Helminths and Malaria which are at the core of the Global Health’s organization.

Jim has a proven track record in Global Health with the development and commercialization of the current MUSE Auto CD4/CD4% system, a laboratory instrument designed to monitor T cells in adult and pediatric patients suffering from HIV/AIDS in developing countries which is marketed since November 2015 by Merck Life Science in many African countries and in Southeast Asia.
Jim has more than 30 years of experience in the pharmaceutical/ diagnostic/ biotechnology industry, including 10 years at Merck Life Science. He has efficiently led sales and marketing organizations at Abbott Diagnostics and Horiba Medical. Before joining Merck, Jim has conducted management in three start-up organizations and has taken these companies from incubation to profit. He has an extensive network with the United Nations and other non-government organizations in the field of Global Health.

Jim holds a BS in Psychology from the University of Houston and attended the Graduate School of Management at the University of Dallas.

Dr. Tariro Makadzange, Ragon Institute of MGH, MIT, and Harvard